These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25619265)

  • 1. Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvir.
    Borentain P; Colson P; Darque A; Gérolami R
    Liver Int; 2015 Jun; 35(6):1776. PubMed ID: 25619265
    [No Abstract]   [Full Text] [Related]  

  • 2. Response letter: Just a matter of luck?
    Donato MF; Malinverno F; Monico S
    Liver Int; 2015 Jun; 35(6):1777. PubMed ID: 25676703
    [No Abstract]   [Full Text] [Related]  

  • 3. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
    Aghemo A; Donato MF
    Gastroenterology; 2015 Jan; 148(1):13-6. PubMed ID: 25451651
    [No Abstract]   [Full Text] [Related]  

  • 4. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
    Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
    Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations.
    Pape E; Scala-Bertola J; Petitpain N; Jouzeau JY; Charrois-Sciaudeau S; Kemmel V; Barraud H; Gambier N
    Transplantation; 2015 Sep; 99(9):e163-4. PubMed ID: 26308424
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of hepatitis C patients with decompensated liver disease.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
    Huysentruyt K; Stephenne X; Varma S; Scheers I; Leclercq G; Smets F; Sokal EM
    Liver Transpl; 2017 Apr; 23(4):552-553. PubMed ID: 28006874
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
    Gallegos-Orozco JF; Charlton MR
    Liver Int; 2015 Jan; 35(1):9-11. PubMed ID: 25412996
    [No Abstract]   [Full Text] [Related]  

  • 11. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Nair S; Satapathy SK; Gonzalez HC
    Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
    Weiler N; Zeuzem S; Welker MW
    World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRO view: treat to prevent recurrence of HCV.
    Everson GT
    Liver Int; 2015 Jan; 35(1):5-6. PubMed ID: 25729804
    [No Abstract]   [Full Text] [Related]  

  • 14. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Post-Liver Transplant Recurrence of Hepatitis C.
    Taylor J; Cox-North P; Landis CS
    Drugs; 2016 Dec; 76(18):1711-1717. PubMed ID: 27878476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
    Mehta N; Yao FY
    Liver Transpl; 2017 Dec; 23(12):1596-1600. PubMed ID: 29024442
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment for hepatitis C before and after liver transplantation].
    Ueda Y; Marusawa H
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():306-10. PubMed ID: 26845950
    [No Abstract]   [Full Text] [Related]  

  • 19. [Recent advances in the treatment of hepatitis C in 2016].
    Luo BF; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):175-180. PubMed ID: 28482403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting agents for hepatitis C virus before and after liver transplantation.
    Sugawara Y; Hibi T
    Biosci Trends; 2018 Jan; 11(6):606-611. PubMed ID: 29238003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.